FDA’s OPaSS promotion
This article was originally published in The Tan Sheet
Executive Summary
Deputy Director of the Office of Pharmacoepidemiology & Statistical Science (OPaSS) will be Jonca Bull, MD, FDA states May 2; the announcement is effective immediately. OPaSS Director Paul Seligman, MD, said Bull "will be responsible for the development and implementation of many of the drug safety and statistical strategic initiatives in OPaSS, in addition to assisting me with the management of the office." She most recently served as director of Office of Drug Evaluation V, which is being eliminated as part of CDER's reorganization (1"The Tan Sheet" Oct. 25, 2004, p. 3)...
You may also be interested in...
OTC Drug Office Take Two: FDA To Elevate Division Through CDER Revamp
A proposed reorganization of the Center for Drug Evaluation & Research Office of New Drugs would re-elevate the Division of OTC Drugs to office status
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.